Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
7.75
+0.11 (1.44%)
Aug 6, 2026, 4:00 PM EDT - Market closed
Kyverna Therapeutics Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Kyverna Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $30.4. The average 1-year stock price forecast is 292.26% higher than the current stock price, while the lowest is $25 (+222.58%) and the highest is $33 (+325.81%).
Price Target: $30.4 (+292.26%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Kyverna Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Reiterates $33 | Buy | Reiterates | $33 | +325.81% | Jul 28, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 27, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $25 | Buy | Reiterates | $25 | +222.58% | Jun 3, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates $30 → $29 | Buy | Reiterates | $30 → $29 | +274.19% | May 13, 2026 |
| Wells Fargo | Wells Fargo | Buy Reiterates $33 | Buy | Reiterates | $33 | +325.81% | May 13, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
17.60M
EPS This Year
-2.88
from -3.64
EPS Next Year
-2.95
from -2.88
EPS and Forward PE are based on non-GAAP adjusted numbers.